The GLP is committed to full transparency. Download and review our 2019 Annual Report

Two US Congressional committees ask IARC cancer agency to testify, citing ‘scientific integrity’ concerns

| | November 2, 2017
Screen Shot at PM
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Two influential U.S. Congressmen have asked the World Health Organization’s cancer agency to get ready to testify about its work assessing if substances cause cancer, citing concerns about its “scientific integrity”.

Their letter to the International Agency for Research on Cancer (IARC), seen by Reuters and sent on Wednesday, is part of ongoing investigations by two Congressional committees into IARC that were fueled by the agency’s review of glyphosate, the primary ingredient of Monsanto Co’s weedkiller Roundup.

A letter to IARC director Chris Wild from the Republican chairmen of the House Committee on Science and the Subcommittee on Environment said they are “concerned about the scientific integrity” of IARC’s “monograph” program, which assesses whether various substances can cause cancer in people.

Related article:  GMO critics claim safety consensus manufactured by industry lobbyists, fellow travelers

In a second letter seen by Reuters, the Congressmen, Lamar Smith and Andy Biggs, expressed concern that IARC’s assessment meetings, deliberations and drafts are not made public.

“It is an affront to scientific integrity to keep ‘confidential’ a scientific process that directly influences policy and individual taxpayers,” Smith and Biggs wrote.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: Exclusive: Congressional committee questions operation of WHO cancer agency

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend